1-Isopropyl-cyclopropylmethylketon | 41527-53-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-Isopropyl-cyclopropylmethylketon
• 英文别名: 1-(1-Isopropylcyclopropyl)ethan-1-one；1-(1-propan-2-ylcyclopropyl)ethanone
• CAS: 41527-53-1
• 化学式: C₈H₁₄O
• 分子量: 126.199
• InChiKey: KVMBMUGSLSHYOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• COMPOUNDS USEFUL AS IMMUNOMODULATORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20170107202A1

  公开（公告）日：2017-04-20

  The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

  本发明公开一般涉及可用作免疫调节剂的化合物。本发明提供了化合物、包含此类化合物的组合物及其使用方法。本发明还涉及包含至少一种根据本发明的化合物的药物组合物，这些药物组合物可用于治疗各种疾病，包括癌症和传染病。
• Azetidinone Derivatives and Methods of Use Thereof
  申请人：Aslanian G. Robert

  公开号：US20080076751A1

  公开（公告）日：2008-03-27

  The present invention relates to Azetidinone Derivatives, compositions comprising an Azetidinone Derivative and methods for treating or preventing a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease, comprising administering to a patient an effective amount of an Azetidinone Derivative.

  本发明涉及吲哚酮衍生物，包含吲哚酮衍生物的组合物以及治疗或预防脂质代谢紊乱、疼痛、糖尿病、血管疾病、脱髓鞘病或非酒精性脂肪肝病的方法，包括向患者投予有效量的吲哚酮衍生物。
• VEGFR3 INHIBITORS
  申请人：CANCER THERAPEUTICS CRC PTY LIMITED

  公开号：US20140073620A1

  公开（公告）日：2014-03-13

  This invention relates to a compound of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.

  本发明涉及公式（I）的化合物。本发明还涉及制备公式（I）化合物的方法，含有该化合物的药物制剂或组合物，或使用该化合物治疗增殖性疾病（如癌症）以及通过控制和/或抑制淋巴管生成改善疾病的治疗方法。
• SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES
  申请人：St. Jude Children's Research Hospital

  公开号：US20190300499A1

  公开（公告）日：2019-10-03

  The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
• US4125541A
  申请人：——

  公开号：US4125541A

  公开（公告）日：1978-11-14